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Abstract
Presently, there is controversy and misconception in the diagnosis and management of most 
congenital vascular malformations. The aim of this manuscript is to identify the current knowl-
edge of these poorly understood and relatively uncommon pathologies. We will also review the 
updated terminology, classiication, pathogenesis, clinical presentation, diagnosis approach and 
management.
© 2014 Revista Medicina Universitaria. Facultad de Medicina UANL. Published by Elsevier México. All rights 
reserved. 
Introduction
Until recently, congenital vascular malformations (CVM) suf-
fered from a bad reputation among health professionals. 
Most doctors did not want to deal with CVM cases due to bad 
experiences in the management of these pathologies, most-
ly due to the lack of information and knowledge, which con-
ditioned bad management and even worse results.1 CVM’s 
misconception has drastically changed due to the better 
understanding of pathophysiology and natural history, as-
pects which facilitated the creation of new CVM classiica-
tions,2 alongside the development of new diagnosis and 
treatment technology and the switch to a multidisciplinary 
approach.3,4 Great results have been accomplished with 
minimal morbi-mortality, few recurrences and a better ac-
ceptance of these complex nosological entities by health 
professionals. 
The purpose of this review is to disclose current knowl-
edge about CVM’s etiology, pathophysiology, genetic as-
pects, diagnosis and therapeutic approach.
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Terms, deinitions and classiications
Vascular anomaly is a term used to describe two pathological 
entities; CVM and vascular tumors represented by neonatal 
or infantile hemangiomas.5 However, these two conditions 
are very different in their anatomy, histology, pathophysiol-
ogy and clinical presentation. CVMs are a result of a failure 
in angiogenesis, appear from birth and grow accordingly to 
the patient’s growth. Hemangiomas are vascular tumors 
originating in the endothelium; generally appearing during 
the neonatal period, they grow rapidly, but later devolve at 
5-10 years of age in the majority of cases. Angioma is an-
other term used indistinctly to name any vascular anomaly 
which causes mistakes and improper management, thus it is 
preferable to avoid its use. On the other hand, there is the 
denomination hemangioma, capillary or cavernous, original-
ly described by Virchow in 1863 to deine vascular anomalies 
present since birth; however, Virchow only took into account 
its location and did not considere other important character-
istics.6 Angiodysplasia is another term coined to described 
CVMs, but due to its limited practical usefulness in describ-
ing a CVM and limited help in differential diagnosis its use is 
not very recommendable.
At the beginning of the 20th century, doctors like Klippel 
and Trenaunay, Parkes and Weberm, Servelle and Martorell, 
to name a few, reported cases of CVM, where in order to 
describe them they used clinical characteristics which in-
cluded alterations in skin, soft tissue, bones and blood ves-
sels and grouped them, creating syndromes which they 
named in accordance with the doctors who irst described 
them.7 These names, based in eponyms, have been used for 
decades and even nowadays are still in use, but do not pro-
vide information about the etiology, pathophysiology and 
anatomy of these complex CVMs. Nevertheless, each syn-
drome has a historical signiicance and although the Ham-
burg classiication is the one that is currently used, these 
classiications are still useful to some extent to describe 
certain mixed forms of CVMs. 
A signiicant step towards clearing the confusion on the 
subject of CVMs was the publication by Mulliken et al8 in 
1982, where a differentiation between CVMs and hemangio-
mas was deinitely made. Moreover, they created a classii-
cation based on the characteristics of the predominant 
endothelium, the hemodynamic state of the vascular mal-
formation (high low: AV, AVM or low low: CM, VM, or LM), 
indings during physical examination and natural evolution 
(table 1). Subsequently, this classiication was redeined by 
Mulliken et al5 in 1988.
Another major development in the classiication of the 
enigma that CVMs represent, was the creation of the Ham-
burg Classiication (HC) (table 2). The Hamburg classiica-
tion is the result of a consensus reached by experts on the 
subject who gathered at the 7th International Workshop on 
Vascular Malformations held in Hamburg, Germany in 1988.9 
This classiication forbids the term angioma, and properly 
classiies CVMs according to the type of predominantly af-
fected vessel or its combinations, and to the embryological 
state where the malformation occurs using anatomic, histo-
logic, and physiopathologic criteria as well as a hemody-
namic state to deine them. It has been accepted by most of 
the medical community because of its proven superiority in 
the application during clinical practice to perform a clini-
cal-anatomical diagnosis, deining treatment and facilitat-
ing communication between different specialists.10 
Within HC (table 2A) CVMs are divided into ive classes, 
depending on the predominant vascular component: arterial 
malformation (AM), venous malformation (VM), lymphatic 
malformation (LM), arterio-venous malformations (AVM) and 
mixed or combined vascular malformations (MVM). At irst, 
capillary malformations were not included in this classiica-
Table 1 Classiication of congenital vascular malformations 
by Mulliken and Glowacky
Low low
Capillary malformation (CM)
Lymphatic malformation (LM)
Venous malformation (VM)
High low
Arterial malformation (AM): aneurysms, coarctation, 
ectasia
Arterio-venous malformation (AVM)
Mixed complex malformations
Regional syndromes
• Sturge Weber: Cara, CM, intracranial CM, VM, AVM
• Klippel-Trenaunay: CM, VM, LM in extremities, thorax 
and abdomen
• Parkes-Weber: VM, CM, LM, AVM in lower extremities
Diffuse syndromes
• Maffucci: VM, LM and endochondromas
• Solomon: CM, VM, intracranial AVM, nevi epidermoids, 
etc.
• Proteus: CM, VM, macrodactyly, hemihypertrophy, 
lipomas, pigmented nevi, scoliosis
Associated with bone hypertrophy
Table 2 Classiication of congenital vascular malformations. 
Hamburg, 1988
A. Malformation type
Predominantly arterial malformation
Predominantly venous malformation
Predominantly lymphatic malformation
Predominantly arterio-venous malformation
Combined vascular malformation
B. Anatomical form (embryological subtype)
Extra-troncular form
• Iniltrative, diffuse
• Limited, localized
Troncular form
• Aplasia or obstruction: hypoplasia, aplasia, 
hyperplasia; stenosis, membrane
• Dilation: localized (aneurism); diffuse (ectasia)
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tion because they were believed to have no clinical signii-
cance and to be equivalent to other CVMs, but in the 1992 
HC revision in Denver11 they were included and later con-
irmed in 2002 in Seoul.12
Each CVM is divided into two types, according to the em-
bryological stage in which it was developed (its clinical pre-
sentation, natural evolution, and the results of the 
treatment depend on this): troncular and extra-troncular 
(table 2B).
The extra-troncular type develops in a very early stage in 
embryological development, in which the vascular system is 
in reticular phase. This type of lesion is composed of rem-
nants of embryonic mesenchymal tissue that preserve an-
gioblast characteristics. These cells retain the potential of 
growing and proliferating with internal stimuli (menarche, 
pregnancy, etc.) or external stimuli (trauma and surgery) 
and present a high recurrence incidence. Extra-troncular le-
sions can be presented as iniltrative and diffuse lesions or 
localized lesions which cause mechanical compression in 
nearby tissues and organs. 
Troncular lesions are formed in the late embryonic stage 
where vascular trunks are being formed,13 and at the same 
time are subdivided into obstructive and/or dilated lesions 
(figure 1). Cells forming this type of lesion have lost the 
ability to proliferate and are presented as a remnant of fe-
tal vasculature, being displayed as aplastic, hypoplastic, or 
Figure 1 Klippel-Trenaunay syndrome. A: capillary malformation (port-wine stain: diffuse, irregular borders and dim color) on the 
lateral face of the thorax and abdomen, lymphatic cyst on the axillary region. B: scoliosis and capillary malformation on the back of 
the chest and abdomen. C: increase in the volume of the ingers secondary to lymphedema. D: hypertrophy and lymphedema of the 
lower extremities. E: venous malformation in the medial aspect of the upper third of the left leg. F: acute complication of 
lymphedema: onicocriptosis and cellulitis of the irst toe.
A B C
D E F
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hyperplastic vessels (aneurysms, vascular networks, etc.). 
Due to the type of these cellular lesions, risk of recurrence 
is low, but the associated hemodynamic consequences can 
be severe. 
After the creation of the Hamburg and Mulliken-Glowacky 
classiications, both with advantages and disadvantages in 
its use, the International Society for the Study of Vascular 
Anomalies (ISSVA) simpliied CVMs classiications in 1996, 
furthermore, adding a vascular tumors section. This classii-
cation is revised every 2 years (table 3).14,15
In the new classiication, the components of the Klippel-
Trenaunay syndromes are deined as CVM constituted by CM, 
VM, and LM, however, in conjunction they are referred to as 
hemolymphatic malformation (igure 1), those from Maf-
fucci syndrome like VM, LM and enchondromas (igure 2) and 
Parkes-Weber syndrome like MVM constituted by CM, VM, 
LM, and VAM. 
On the other hand, Puig et al16 classiied venous vascular 
malformations in function of their anatomic location, where 
they drain and their hemodynamic characteristics, a result 
that is especially useful to assess the eficacy of sclerosis 
therapy. In order to deine the lesion’s hemodynamic char-
acteristics, a phlebography must be performed, and with 
the results from this procedure venous malformations are 
divided into four types: I. isolated malformations without 
peripheral drainage; II. malformation that drains into nor-
mal veins; III. malformations that drain into dysplastic 
veins, and IV. malformations that drain into dilated veins. 
Types I and II are the easiest to treat and have a better re-
sponse to sclerotherapy. 
Epidemiology
CVM incidence is 0.3-1.5%; it is high compared to congenital 
heart diseases (0.88%) or spina biida (0.2%), but lower than 
hemangiomas, which have an incidence of 2-3% in newborns 
and increases to 10% at the end of the irst year of life.5,17,18
Distributions between the different CVMs are as follows: 
venous malformations (VM) 48.5%, arterial malformations 
(AM) and arterio-venous malformations (AVM) 35.8%, lym-
phatic malformations (LM) 10%, and mixed combined mal-
formations (MCM) 5.7%. Regarding CVM subtypes, the most 
frequent are extra-troncular, corresponding to 57%. In the 
distribution by gender, male-female ratio for VM is 1:1.2, 
VAM is 1:4 and LM is 1:1.
Capillary malformations (CM) appear from birth, MVs are 
present from birth, but become visible and symptomatic 
during childhood or later, MLs can manifest from birth up to 
adulthood (figure 4) and VAMs appear fundamentally in 
childhood and adolescence (igure 5). 
Regarding their location, troncular malformations are 
more frequently observed in the limbs and extra-troncular 
malformations in the head and neck.19
Genetic aspects and pathophysiology
Vascular malformations are benign, non-tumor lesions, al-
ways present since birth, although sometimes not visible un-
til weeks, months or years later.20,21 They are diffuse or 
localized mistakes in the embryological development, usu-
ally attributable to sporadic mutations. However, recent evi-
dence points to a possible family hereditary factor. Kikkula 
et al22,23 found a mutation characterized by an increment in 
the activity of the tyrosine kinase Tie2 receptor (tunica inti-
ma endothelium kinase 2) in two families with venous mal-
formations. Tie-2 is essential for early vessel development 
and an increase of its activity may produce an abnormal 
growth of the primary vascular plexus.24 The same workgroup 
has also described glomulin implication in patients with ve-
nous malformations (glomuvenous).25 Furthermore, some ge-
netic mutations are known in cerebral cavernous mutations26 
and in combined vascular malformations of the Klippel-Tre-
naunay-syndrome and Proteus syndrome type.28 Along the 
same lines, alterations in vascular neurological modulation 
have been described in at least two types of vascular malfor-
mations.29,30 Thus venous malformations are probably caused 
by a relative or absolute deiciency in the autonomic enerva-
tion of post-capillary venous plexus, while arterio-venous 
malformations may be caused by the same alteration, but at 
precapillary sphincter levels.31
In order to explain the etiology of a CM —which appears 
like a port-wine stain on the skin—, the term “sick derma-
tome” has been coined, for which a lesion is caused by an 
absolute or relative deiciency of the autonomic and sensory 
vascular innervation which originates the growth of the af-
fected vessels, being able to reach the typical cobblestone 
aspect. If the defect is total, the changes will be faster as 
time goes by. The histological study of these hypertrophies 
has proven diffuse hamartomatous changes, also affecting 
Table 3 Modiied classiication of the International Society 
for the Study of Vascular Anomalies (ISSVA), 1996
Tumors
Hemangiomas Supericial (capillares)
Deep (cavernous)
Mixed
Other Hemangioendothelioma kaposiform
Tufted angioma 
Aemangiopericytoma 
Hemangioendothelioma 
Glomaangioma 
Pyogenic granuloma 
Kaposi sarcoma 
Angiosarcoma
Vascular malformations
Simple Capillares (C)
Venous (V)
Lymphatic (L)
Arterial (A)
Combined Arterio-venous (AV)
CLV (Klippel-Trenaunay)
CV (some cases with Klippel-Trenaunay)
LVM
CAVM
CLAVM
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blood vessels, epithelial connective tissue and neural skin 
elements, which suggest the existence of somatic mutation 
in the implicated area.32 On the other hand, precapillary 
sphincters in charge of regulating blood low may have an 
autonomic innervation defect or some deficiency of the 
neuroreceptors in this location and be the cause of the ori-
gin of arterio-venous malformations. Depending on whether 
the defect is absolute or relative, the age of presentation 
and progression of evolutions will vary. Contrary to heman-
giomas, vascular malformations do not have a growth cycle 
or subsequent spontaneous regression, but they persist for-
ever and slowly grow throughout life, sometimes in relation 
with trauma, changes in blood or lymph pressure, infectious 
processes, hormone changes, etc. In these lesions it is char-
acteristic for a vascular ectasia to be produced progressive-
ly, increasing the diameter but not the number of the 
vessels and expanding through hypertrophy, but not by hy-
perplasia, like hemangiomas do. In either case, this classical 
concept can be open to modiication, because it presents 
several exceptions. For example, arterio-venous malforma-
tions frequently grow by hyperplasia and they may behave 
like authentic tumors. Despite the fact of an apparent endo-
thelial quiescence, some vascular malformations may ex-
pand rapidly during pregnancy, after a surgical treatment or 
in response to a trauma. The pathogenesis of vascular mal-
formations is not yet clear but its formation and progression 
are extremely related with angiogenesis.
Angiogenesis constitutes a complex process regulated by 
many factors which lead to the formation of a new func-
tional vascularity, and includes endothelial cell differentia-
Figure 3 Early-onset primary lymphedema of the right lower 
extremity in a 10-year-old female patient.
Figure 2 Maffucci symdrome. 
A: venous malformation (VM) on 
the lateral side of the neck. B: VM 
cysts, clustered in the anterior, 
lateral and posterior of the tho-
rax. C: VM depressible, bluish, in 
the form of grape bunches which 
empty upon raising the hand and 
enchondroma in the phalanges. D: 
VM on the external side of the left 
heel.
A B
C D
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tion, murals (pericytes), cellular proliferation and 
migration and the speciication of blood vessels, venous or 
lymphatic.33 
Even though to this day we do not know of a study that 
proves the existence of an angiogenic ceric profile in an 
adult patient with vascular malformations, it can be in-
ferred, at least in theory. Marler et al34 observed levels of 
metalloproteinase and bFGF (basic ibroblast growth factor) 
in the urine in children with hemangiomas and vascular mal-
formation in comparison to a control group. Another essay 
shows increased bFGF serum levels in a patient with glo-
mangiomas.35 Moreover, some clinical observations and mo-
lecular studies proved that cerebral arterio-venous 
malformations present angiogenesis and vascular remodel-
ing.36 All those indings suggest a signiicant role of angio-
genesis in the development and maintenance of vascular 
malformations, perhaps not as abrupt and limited in time as 
it occurs with the proliferation phase of hemangiomas,37,38 
but not negligible at all when it comes to explaining the 
pathophysiology of these lesions.
Clinical presentation
A CVM’s clinical presentation depends on the type of affect-
ed vessel, the location of the anatomical malformation and 
whether it is localized or diffuse. As previously mentioned, 
CVMs can affect arteries, veins, lymphs or capillaries inde-
pendently, or appear affecting two or more types of vessels, 
these are called mixed lesions and are particularly named 
accordingly to the affected vessels (i.e. hemolymphatic 
malformation). The variety of clinical presentations is di-
verse and countless. In many cases clinical history and phys-
ical examination are enough to establish a diagnosis, 
nevertheless, on other occasions and especially among the 
pediatric population, it is very hard to stablish a correct di-
agnosis.
Capillary malformations
CMs are typically presented as port-wine stains on skin; they 
can be located in any part of the body, their way of presen-
tation varies from small and localized lesions to extensive 
lesions covering several areas of the body and may iniltrate 
deep tissues.
CMs may be accompanied by other vascular malforma-
tions and complex syndromes, like Sturge-Weber, which is 
the association of a CM of the face accompanied by ocular-
vascular malformations and ipsilateral leptomeninges. CMs 
should be differentiated from lesions like nevus lamemeus 
neonatorum, also known as “salmon patches”; these are 
pink lesions located on the nape of the neck, forehead, eye-
lids or lips (“angel kisses”).39 In order to explain the presen-
tation of CMs, the term “sick dermatome” was coined, thus 
a CM is caused by an absolute or relative deiciency of the 
autonomic and sensory vascular innervation at this level 
which originates hypertrophy of the affected vessels, possi-
bly reaching the typical cobblestone aspect. Port-wine 
stains affect one or more facial dermatomes determined by 
the trigeminal nerve branches. V2 dermatome is the most 
affected (57%), followed by mandibular V3 and ophthalmic 
dermatome. They can be affected in an isolated or grouped 
manner.40
Venous malformations
VMs are the most frequent CVM, are low low, slow growth, 
localized or diffuse and in general of sporadic presentation. 
VMs are presented as soft, ballooned, compressible, bluish 
lesions located superficially in the skin layers which lose 
their volume when the affected limb is raised, and increase 
upon dependence or with Valsalva maneuvers. At touch 
(palpation) there are no increases in temperature, thrill 
cannot be felt, and unless there is a thrombosis they are not 
painful.41 VMs can affect the skin, subcutaneous cellular tis-
sue, muscles, limbs and any organ. Depending on their size, 
location and the patient’s hormonal state VMs can cause 
moderate to severe pain. When they affect lower limbs they 
can cause weakness, muscular hypertrophy or hypotrophy, 
bone growth disorders, pathologic fractures and mild to 
moderate morning pain or rigidness, which improves with 
compressive therapy.42 When knee articulation is affected, 
this becomes susceptible to lesions caused by minor trauma, 
manifesting itself with repetitive hemartrosis, resulting in 
ankyloses or degenerative arthritis.43 Migraines are a com-
mon characteristic of VMs located on the face or temporal 
muscle. When they affect abdominal muscles, airways, or 
the central nervous system they may become complicated, 
with symptoms provoked by bleeding, obstruction or com-
pression. VMs located in the head and neck are usually pre-
Figure 4 Late-onset primary lymphedema of both lower ex-
tremities with the presence of chronic skin changes in a patient 
of 62 years.
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sented in a unilateral way, provoking a mass effect causing 
distortion and asymmetry of facial structures.44 When they 
affect the tongue, palate and oropharynx they result in a 
signiicant deformity, causing dental malocclusion and if it 
invades airways it can cause life-threatening lesions.45 Any 
part of the digestive tract may be implicated, it can be pre-
sented as nodular, sessile or polypoid lesions which provoke 
chronic bleeding. In troncular venous lesions which manifest 
as venous dilation or real aneurysms, there is a thrombo-
philic risk, therefore the presence of venous thrombosis and 
pulmonary embolism is common.46,47
Lymphatic malformations
Since the establishment of the HC, the LM denomination has 
replaced the older names of cystic capillary hygroma and 
microcystic and cavernous lymphangioma, which corre-
spond to extratroncular lesions and manifest as a benign 
mass, consisting of thin vessels and cystic structures of dif-
ferent sizes, well-defined, of a soft-spongy consistency, 
which are usually asymptomatic as long as there are no 
complications (i.e. intralesional bleeding, infections, lym-
phorrea),48 and are of great clinical interest because their 
growth may compromise the organs where they are located. 
They are mainly located in the head and neck and armpit, 
but also can be found in the mediastinum, limbs and retro-
peritoneum. They constitute 5% of benign masses in child-
hood, up to 60% of the cases can be observed from birth, 
90% before 2 years of age and the rest can appear prena-
tally or suddenly in ulterior stages of life but usually before 
turning 16 years old.49,50
When they affect the oral mucous, tongue, upper or lower 
maxilla or neck they can also cause esthetic sequels, dys-
pnea, dysphonia, dysphagia and bleeding, in addition to en-
dangering the patient’s life.51,52 If it affects the ocular 
region, proptosis, strabismus, or loss of vision may occur.53 
Extratroncular LM can also directly or indirectly affect bone 
metabolism (Gorham syndrome), which causes bone over-
growth and pathological fractures. Troncular LMs manifest 
as primary lymphoedema, of premature, early or late on-
set54 (igures 3 and 4).
Arterio-venous malformations
AVMs correspond to a vascular system anomaly which re-
sults in an arterio-venous shunt, which may go unnoticed or 
cause cardiac failure.55 The majority of AVMs are detected 
in patients between 20 and 40 years of age. The vessels of 
which AVMs are constituted consist of a thin wall, very frag-
ile and fed by dilated arteries, which have in their walls a 
deiciency of elastin, connective tissue and smooth mus-
cle.56
Most AVMs occur in independent lesions but these can also 
be linked to other CVMs making its diagnosis and treatment 
more complex.57 AVM incidence is much less than VM or LM 
but are hemodynamically more complex and more common-
Figure 5 Arterio-venous malfor-
mation in a patient of 57 years 
which caused ulcers in the lower 
left extremity in the external 
malleolar (A) and medial (B) re-
gion which was accompanied by 
refractory pain to medical treat-
ment and the diagnosis of AVM was 
confirmed by ultrasound and an-
gio-MR (C).
A
B C
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ly endanger the patient’s life.4 They differentiate from oth-
er CVMs because of their varied clinical presentations, 
unpredictable natural history, high recurrence rate and el-
evated morbi-mortality. 
AVMs in soft tissue manifest as a located volume incre-
ment, accompanied by a rise in local temperature, thrill 
presence, murmur and dilated veins (characteristic triad of 
AVMs). Ischemic changes and skin ulcers may occur distal to 
an AV short circuit, usually accompanied by refractory pain 
to medical treatment and intermittent bleedings (igure 5). 
AVMs may occur in any part of the body, however, over 50% 
are located in the brain or spine. Those located in the cen-
tral nervous system can appear in the clinical setting as a 
stroke with clinical manifestations that depend on where 
the lesion is located.58
Diagnosis
In order to make a proper diagnosis and be able to offer the 
ideal treatment, we can use the following questions as a 
guide: Is it an hemangioma (vascular tumor) or a CVM?, what 
type of CVM is it?, what is the anatomic location?, and which 
hemodynamic alteration does it cause?
To be able to properly answer these questions, it is neces-
sary to irst have the knowledge of the different CVMs and 
vascular tumors so that through clinical history and physical 
examination we will be able to have a diagnostic orientation 
and subsequently choose among the different complemen-
tary tests to conirm suspicions.
The objective of a correct diagnosis is to deine the type, 
location, extension and hemodynamic alterations of a CVM, 
in addition to choosing the best therapeutic option and fol-
low up on its evolution. Diagnostic tests can be divided into: 
a) functional tests, useful to evaluate the physiology and 
hemodynamic of lesions, Doppler ultrasound and plethys-
mography are among these studies; b) anatomo-functional 
tests represented by the echo-duplex which is the irst op-
tion for a CVM assessment, and can provide information of 
the characteristics of the lesion and its hemodynamic be-
havior, and c) imaging studies, which include simple x-rays, 
MRI, CAT scans, angiography, phlebography, lymphangiogra-
phy and nuclear medicine studies like lymphangio-scyntil-
lography and full body gammagraphy, among others. 
Ultrasound
The irst test to be considered in the evaluation of a patient 
with suspected CVM is the duplex ultrasound.59 It has the 
advantage of being easy to access and provides information 
about the anatomy of the lesion as well as its physiology. In 
addition, it is used for echo-guided endovascular treat-
ments. This test allows for an immediate differentiation be-
tween low-low (VM or LM) or high-low lesions (AVM). VMs 
are shown as hypoechoic (82%), hyperechoic (8%) and 
isoechoic (10%).60,61 Occasionally phleboliths (as acoustic 
shadow) appear, which are pathognomic of the VMs. VMs 
low in most of the cases appears as monophasic or biphasic 
(84%), and it increments after the completion of compres-
sion maneuvers; up to 16% do not present low. It is impor-
tant to determine whether or not there is a venous low in 
the system (supericial or deep), as well as determine the 
anatomical characteristics of both systems and not to forget 
to assess the lateral side of the thigh where the marginal 
vein is usually found.62 We are able to see phleboliths which 
are round, non-compressible masses and with acoustic 
shade.63 In LMs echography is the perfect technique for the 
assessment of supericial lesions. In addition to being low 
low, they can appear as macrocystic or microcystic lesions, 
appearing as hypoechoic or anechoic, and multiloculated 
with septa of variable thickness. Microcystic lesions with or 
without low can be confused with VMs.64
AVMs appear as lesions with high systolic low and are hy-
perdense because of the hypertrophy of the affected ves-
sels. An ultrasound is also effective to assess the damage in 
soft tissues and muscles.65
Magnetic resonance
If the clinical history and the ultrasound indicate a low-low 
CVM, magnetic resonance imaging (MRI) is the next study 
that should be performed, and if the diagnosis indicates 
high-flow, the angio-MRI and CAT scan are the indicated 
studies.66,67
MRI provides an excellent tissue differentiation that, 
along with the ability to obtain images in multiple spatial 
planes, makes it the best radiologic examination and a irst 
choice study to demonstrate the anatomical relations and 
study surrounding tissue in contact with vascular malforma-
tions. Besides providing anatomical information, it is also 
capable of providing hemodynamic data, due to the phe-
nomenon in which the MRI technique is based, the presence 
of fast or turbulent flow will condition a decrease in the 
signal’s intensity, while in those cases where there is a low 
low or thrombosis the intensity will increase.68,69
VMs commonly appear as lobular lesions (single or multi-
ple), displaying high and homogenous intensity, of a serpigi-
nous structure or like iniltrate masses; phleboliths appear 
lacking a signal (Void sign).70
In LMs, it is not possible to observe a contrast, except for 
in the microcystic components or in the case of complex 
malformations of the lymphatic-venous type.71 AVMs, differ-
ent from the rest, lack a solid component. The MRI studies 
reveal characteristically the presence of high-low vessels 
shown as serpiginous morphology zones with a lack of signal 
in T1 as well as T2 sequences.17
The use of angiographic sequences allows for the detec-
tion of vascular structures and even the creation of a three-
dimensional angiographic map when they are combined 
with the MIP (maximum intensity projection) reconstruc-
tions.72 MRIs are of a great value when it comes to the anal-
ysis of an AVMs extension, as well as the degree of invasion 
of the anatomically affected structures.73
Computerized axial tomography
One of the advantages of the computerized axial tomogra-
phy (CAT) scan is the excellent demonstration of bone struc-
tures and calciications it provides. Nevertheless, soft tissue 
deinition is clearly lower than that offered by MRI studies. 
Among the disadvantages are that it is a technique based on 
the use of ionizing radiations which almost always needs to 
use contrast medium, that do not turn out to be innocuous 
due to their nephrotoxicity and possible adverse reactions, 
which on occasions can be severe.74 Also, in the case of pe-
diatric patients, the use of sedation becomes necessary be-
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cause the quality of the studies seems clearly diminished by 
movement. Even though the hemodynamic information pro-
vided by CAT scans is very limited, nowadays with the use of 
the new multislice equipment, which allows very fast image 
acquisition, it is possible to perform multiplane reconstruc-
tions of great quality as well as angio CAT studies. In the 
case of venous malformations, a CAT scan can show the 
presence of calciications in relation to phleboliths and al-
terations in surrounding bone structures. 
In spite of the administration of intravenous contrast me-
dium, using this imaging technique may result in a dificulty 
delimiting the lesion in relation to the adjacent muscular 
planes. The lymphatic malformations appear as cystic le-
sions full of a homogenous liquid with an attenuation value 
similar to that of water, although in the lesions with liquid 
content rich in lymph, the attenuation is closer to that of 
fat. Cases that have been complicated by an infection may 
have a more heterogeneous density. Frequently, the walls of 
the cysts show a certain degree of enhancement after ad-
ministration of an intravenous contrast.75 The CAT scan is 
also capable of showing anomalies in the bones related to 
arterio-venous malformations, although it does not give us 
speciic information on vascular structures in relation to ad-
jacent tissues.
Simple radiography
Simple radiography (SR) is useful for detecting the second-
ary effects of CVMs in bones and soft tissue (e.g. osteo-vas-
cular syndrome, Gorham syndrome). An SR can detect 
calciied phleboliths, typical of venous vascular malforma-
tions. It can also evaluate bone changes (cortical thicken-
ing, demineralization, or osteoporosis) which can appear in 
up to 20% of extensive vascular malformations of the limbs.76 
It develops in patients with extensive CVMs in their extrem-
ities, permitting measurement of their length and knowing 
exactly if dysmetry exists between either of them. Clinical-
ly, it is only possible to detect differences in length between 
0.5 and 1 cm, which means that to evaluate lesser distanc-
es, we need to employ these imaging methods. On the other 
hand, it permits us to determine the rate of growth of each 
extremity, know if the dysmetries are progressive or stable 
and evaluate the best moment to perform the necessary 
therapeutic treatments to equalize the length of the ex-
tremities, aspects which are not possible to evaluate clini-
cally. These radiographic procedures are rarely necessary 
before 2-3 years of age, nor after skeletal maturation, be-
cause the differences in the length of the extremities does 
not progress past the closure of the epiphysial cartilage.77 
Because of this, we recommend performing a clinical and 
radiological measurement beginning at 2 years of age and 
be repeated annually.
Venography
In a venography result it is useful to know the anatomy of 
the supericial and deep veins, the state of the valves, the 
presence of embryonic veins, the connections between the 
deep and supericial systems, and the degree of venous in-
competence. Disadvantages are the possibility of allergic 
reactions and of venous thrombosis owing to the use of io-
dinated contrast medium.
Arteriography
An arteriography may be necessary when the presence of 
arteriovenous istulas is suspected, especially those with 
low low, which are dificult to evaluate with other tech-
niques. Apart from its diagnostic value, an arteriography is 
the way to perform a therapeutic embolization on an AVM.
Lymphangiogram
Historically, the lymphangiogram represents the ideal study 
for the evaluation of the lymphatic system. It contributes 
information on lymphatic drainage, the size of the vessels, 
alternative paths, and morphological alterations. It is a 
technique that is very dificult to perform and the contrast 
medium which is used can cause complications. The direc-
tions limit the evaluation of the lymphatic vessels in case of 
persistent lymphoedema, or in extensive combined malfor-
mations, when the difference in the diameter of both ex-
tremities exceeds 4 cm. Although this deals with a technique 
in disuse because of its complexity and slow performance, it 
can contribute very signiicant information which can be 
dificult to obtain by other means in some vascular malfor-
mations with associated lymphatic malformations of the 
thoracic cavity.78
Nuclear medicine
In the evaluation of CVMs we can count on three studies of 
nuclear medicine: a) the total body scintigraphy (TBS) with 
labeled erythrocytes, which has much value in the initial 
evaluation, giving information on the extent, physiology, 
type and subtype of the CVM; it is very useful when MRI re-
sults are ambiguous;79 b) linfangio-scintigraphy,80,81 which 
has taken the place of lymphangiography and currently is 
the study of choice to conirm a diagnosis in patients with 
suspected lymphoedema; and c) the transarterial lung per-
fusion scintigraphy,82 which is used to evaluate AVMs and 
quantify and verify arterio-venous shunts.
Treatment
Szilagyi83 said, in 1965: “no surgical treatment should be 
directed in the management of any CVM and it should be 
considered as a palliative measure only in cases where the 
beneits far outweigh the risks, owing to the fact that CVMs 
cannot be cured through any surgical procedure.” This rec-
ommendation was followed by the medical community for 
decades but, with a better understanding of CVMs, this con-
cept of incurability has changed. Every patient and any type 
of CVM should be evaluated by a multidisciplinary team, 
whose consensus will determine, after an exhaustive evalu-
ation, the treatment of choice.84
Dr. B.B. Lee85 established, in a simple and understandable 
manner, the instructions for the treatment of CVMs. He di-
vided them into absolutes and relatives. Among the abso-
lutes were found: a) bleeding; b) cardiac failure secondary 
to a high low AVM; c) complications secondary to venous 
hypertension; d) critical ischemia of an extremity due to 
the arterial steal phenomenon, and e) lesions which pro-
duce compression on important organs (respiratory tract, 
eyes, ears, etc.). Relatives include: a) severe, progressive 
and incapacitating pain; b) intermittent claudication; 
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c) functional damage which occasionally incapacitates and 
loss of quality of life; d) deformities with aesthetic reper-
cussions, which cause personality disorders; e) asymmetry 
in the length of the extremities, and f) recurring infections.
Conservative treatment is indicated in symptomatic pa-
tients when: a) they do not conform to the above-men-
tioned criteria; b) the lesion is not manageable by invasive 
treatments due to the anatomic location, the calculated 
risk being higher than the expected beneits, or the patient 
not signing the informed consent form, and c) the patient is 
receiving follow-up subsequent to undergoing surgery or 
minimum-invasion procedures. Within the conservative 
management, a measure of great importance is the use of 
means of gradual compression (helps to slow the progression 
of VMs or LMs, controls pain and decreases the incidence of 
complications).86 Due to the thrombophilic risk which pa-
tients with a large volume VM present, the use of a prophy-
laxis of low-molecular weight heparin is recommended 
during high-risk episodes like surgery, pregnancy, or long 
periods of bed rest. The use of aspirin and the suspension of 
oral contraceptives is also recommended, which diminish 
the paroxysms of pain.
The main objective in the treatment of all CVMs is the cor-
rection of the hemodynamic repercussions which produced 
the malformation and later treatment of the soft tissue and 
musculoskeletal alterations which accompanied the primary 
pathology. The optimal combination of surgical procedures 
with endovascular treatments, like liquid or foam sclero-
therapy or embolization and ablation by radiofrequency or 
laser, should be performed in accordance with embryology, 
on which depends the potential of recurrence of the lesion 
(extra-troncular lesions are iniltrative and dificult to eradi-
cate, with a high incidence of recurrences and complica-
tions) and the hemodynamic nature of the primary lesion. 
The treatment of secondary lesions frequently merits the 
performance of orthopedic and/or reconstructive surgery.
Venous malformations
As mentioned above, VMs are subdivided into two types: ex-
tra-troncular, which are iniltrative, with a little or great su-
pericial component, generally cause a lot of pain and have a 
complex treatment; and the troncular type, which manifest 
as more supericial lesions that could be mistaken for venous 
hypertension symptoms secondary to relux, present discom-
fort such as a feeling of heaviness in the legs, cramps and 
mild to moderate pain. Its treatment is simpler. We must 
acknowledge that both VM types can be present in the same 
patient. Conservative treatment is recommended for most 
VMs without bone involvement, in pediatric patients up to 
the age of 2 to 3 years old, where the patient is in a condi-
tion to tolerate the necessary diagnostic and therapeutic 
procedures, keeping in mind that in the case of a lesion 
which endangers the patient’s life or causes asymmetry of 
the extremities or bone deformities, the therapeutic ap-
proach would be more aggressive from an early age. 
VMs can be treated through endovascular therapy or sur-
gery. Both have their advantages and disadvantages. The 
complex nature of VMs makes the treatment more dificult. 
Surgery has a limited usefulness in the case of very iniltra-
tive VMs or VMs located in places that are dificult to reach. 
Additionally, because VMs can respond with rapid growth to 
surgical trauma,87 making a latent lesion into a more ag-
gressive one, in most of the cases endovascular therapy is 
preferred. 
In endovascular therapy embolization, sclerotherapy, em-
bolization and techniques of endovascular ablation with la-
ser or radiofrequency are used. Embolization is deined as 
the occlusion of a blood vessel through the introduction of a 
foreign body; this technique is not the most recommendable 
for VMs, because these are formed by very dilated vessels, 
which generally cannot be 100% obstructed by the different 
utilized agents (i.e. coils, cyanoacrylate). Also, these lesions 
are irrigated by many vessels, making it extremely complex 
to occlude each one of them,88,89 in these cases sclerothera-
py is preferred, which consists of injecting a substance (scle-
rosant) in liquid form or foam directly into the lesion, this 
causes endothelial damage, inlammation, thrombosis and 
fibrosis resulting in obliteration (sclerosis) of the treated 
vessels.90,91 Sclerosant agents used in VM treatments include: 
ethanol,92,93 sotradecol,95 Ethibloc96 and ethanolamine ole-
ate.97 Ethanol, which has been used for over one hundred 
years, is considered the most effective of the sclerosant 
agents but also the most aggressive and with a higher inci-
dence of local (pain, skin necrosis, compartmental syn-
drome, cellulitis, nervous lesion) as well as systemic 
(pulmonary hypertension, arrhythmias, nervous depression, 
pulmonary embolism, etc.) complications (7-27%),98 which 
may put the patient’s life at risk. For these reasons, in North 
America the use of sotradecol is preferred; in Europe polydo-
canol is the agent of choice and in Mexico, the latter is the 
only one available. Sclerosant agents can be administered 
using an injection or with the placement of a catheter, guid-
ed with the help of an ultrasound, MRI or CAT scan.99,100 Suc-
cess rates for these techniques varies from 60 to 90%.101-103
Many VMs located in the pelvis or lower limbs cause ve-
nous relux to the supericial venous system, causing compli-
cations by venous hypertension. Treatment with laser or 
radiofrequency is indicated improving the patient’s symp-
tomatology and avoiding recurrences.104,105 
Surgical treatment for VMs can be performed following 
different therapeutic guidelines:106,107
I. Surgery to reduce the hemodynamic effects of VMs 
(venous hypertension). This approach is not radical 
and it is indicated when it is not possible to per-
form reconstruction or completely eradicate a VM; 
with this technique a considerable reduction in ve-
nous stasis and venous hypertension is accom-
plished, considerably improving the condition of 
patients who were considered inoperable.
II. Surgery to completely eliminate VMs. This type of 
surgery is indicated in peripheral lesions secondary 
to extra-troncular VM, generally obtaining accept-
able results and it is indicated before suggesting a 
reconstructive orthopedic surgery. This is a radical 
surgery, following the Malan method applied in on-
cologic surgeries.108
III. Reconstructive surgery. This technique is rarely ap-
plied in VMs due to its iniltrative nature and the 
pathological structure of the vessel wall. It may be 
indicated in venous defects localized in an organ or 
lower limb, causing obstruction of the aneurismal 
vessels.109,110
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Lymphatic malformations
Treatment for troncular LM clinically presented as primary 
lymphoedema is usually conservative. It consists of what is 
known as lymphatic decongestive therapy which includes 
lymphatic drainage, either manual or with the use of pneu-
matic compressors, physical therapy exercises, proilactic 
measures in order to prevent complications and the use of 
graded compression measures.111 When LM anatomy is ade-
quate, reconstructive surgeries can be performed, like 
venolymphatic or lymph-lymphatic anastomoses or a lymph 
node transplant using microsurgery techniques, which im-
prove the volume of the affected limb and the patient’s 
quality of life.112-114
In the case of extra-troncular LM, most appear as inde-
pendent lesions called lymphangiomas. Treatment is indi-
cated in cases where the LM is located in areas which 
compromise a vital function, or if there is bleeding, recur-
rent infections, lesions with lymph drainage or lesions with 
VM components. The irst line of treatment for these types 
of malformations is the use of sclerosants via endovascular 
treatment. OK-432 sclerosant, also known as Picibanil, is 
the option to start extratroncular LM therapy. OKK-432 is 
the lyophilized exotoxin of the Streptococcus pyogenes 
type III of group A.115 This lymphatic sclerosant acts over the 
congenital malformation through a cascade of antitumor 
agents secreted by neutrophils, macrophages, natural “kill-
er” lymphocytes (CD56+) and T cells (CD3+) which activate 
the immune system, causing an increase of the endothelial 
permeability, drainage and lymph low, resulting in the re-
duction of the lesion by contraction of the cystic spac-
es.115,116 Macrocystic lesions are easy to inject, with 
excellent results and a low morbidity (igure 6). On the oth-
er hand, microcystic lesions in many occasions are impossi-
ble to inject. Furthermore, this type of lesion usually drains 
into the normal lymphatic system, possibly damaging it. In 
both cases more than one therapeutic session is needed. In 
case OK-432 is ineffective, ethanol will be used. Ethanol is 
an excellent sclerosant with few recurrences, but with a 
higher morbidity. It is recommended only for macrocystic 
lesions.102 Bleomycin is an antitumor cytotoxic antibiotic 
with a double effect: on the one hand it induces ADN15 deg-
radation and on the other it displays a sclerosing effect over 
the vascular endothelium. Because of this, it has been given 
an intralesional use in LM.119,120 Posterior to the sclerothera-
py session, hospitalization is recommended in pediatric pa-
tients. Also, there have been reported cases using sildenail 
(orally) with good results.121
Surgical treatment of LM is limited to cases where sclero-
therapy was unsuccessful, or in the case of microcystic le-
sions associated with other CVMs (mainly venous) too 
dificult to treat with sclerosant.54,122 Ideally, radical surgery 
should be performed, in order to avoid recurrences. How-
ever, in areas involving important structures, a partial re-
section is acceptable. The ideal time to perform surgery is 
as yet unclear, but it is recommended to delay the proce-
dure as much as possible.
Laser treatment of LM as endovascular or transdermal 
procedures with a laser with a wave length of 1470 nm, has 
been reported by some authors,123 being a minimally inva-
sive procedure, as a valid therapeutic alternative against 
conventional therapies, performed as a single procedure or 
associated with other therapies. 
Arterio-venous malformations
Out of all CVMs, AVMs are the ones with the more complex 
treatment and when presented in combination with other 
types of CVM, are the ones with priority in treatment. The ob-
jective of the treatment is to completely eradicate the malfor-
mation, or at least reduce its hemodynamic effects. Available 
alternatives for AVM treatment include: embolization, sclero-
therapy, surgery and laser therapy. The treatment of choice for 
AVMs nowadays is still surgery; nevertheless, surgical therapy 
only works in an incomplete treatment linked to a high morbid-
ity. Thus, unless the AVM is localized and easily removed, sur-
gery should be combined with an endovascular approach, using 
sclerotherapy or embolectomy.124,125 Endovascular techniques 
were at irst introduced by the treatment of lesions not cur-
able with surgery, but once good results were shown in this 
type of lesion, they decided to combine it in most AVM cases, 
either in the preoperative (in most cases), trans-operative or 
postoperative period, obtaining better results and fewer recur-
rences and morbidities.126 The utilized sclerosants are the 
same as in VMs and in the same manner, ethanol is the most 
effective yet risky (see venous malformations).
Figure 6 A: male patient of 6 years 
with a macrocystic lymphatic mal-
formation on the side of the neck 
(cystic hygroma). B: 2 months af-
ter treatment with OK-432.
A B
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The moment of surgery is important because the more 
mature the lesion is, the more dificult it is to complete a 
full excision. Therefore, resection should take place as soon 
as possible and should be as complete as possible. Resection 
margins should be wide regarding the limits of the lesion. 
The use of preoperative magnetic resonance and digital an-
giography, especially evaluated dynamically, are particular-
ly useful to establish these margins.
Capillary malformations 
Treatment is indicated in all symptomatic lesions and those 
that are visible that may cause emotional stress. Among the 
CM treatments are: a) laser photocoagulation, which is irst 
choice of treatment; the objective of the laser therapy is 
selective thermolysis with the wavelength which produces 
the most lightening with the least number of sessions and 
lower morbidity; it is useful as long as the lesion is lat and 
better results are obtained when the patient is younger and 
with a lighter skin; greater amounts of melanin will reduce 
the possibility of a response to the laser; b) camoulage; 
makeup techniques may play a signiicant role as well; it is 
useful as long as the lesion is lat; c) cryosurgery: this is re-
served for those cases where the lesion presents hypertro-
phy and skin with a nodular aspect or presence; in these 
cases, laser loses its effectiveness while cryosurgery in-
creases it in reducing the thickness of hypertrophied skin 
and eliminates nodules, and d) other treatments employed 
in lat lesions, like steroids, radiotherapy, cryotherapy and 
electrocoagulation, have had limited success. 
Mixed malformations
In this CVM group, the priority is to irst treat the AVM com-
ponent (as mentioned throughout the article) if there is 
one. A coexistence of VM and LM is the most typical combi-
nation.128 When dealing with mixed lesions we are able to 
apply the previously mentioned principles for venous and 
lymphatic malformations, modifying them according to the 
degree of implication of each of the systems. The venous 
component is treated irst because an alteration in the func-
tioning of the lymphatic system can occur because of the 
interrelation of both systems; in other words, to treat the 
venous component of mixed malformations like Klippel-
Tranaunay syndrome vigorously, the patient, which depends 
on its lymphatic component, may worsen notably. Hence, 
the most appropriate treatment choice becomes relevant. 
In order to plan the therapeutic strategy, the physician must 
know in detail the type of malformation, anatomic location 
and hemodynamic composition, in order to prevent compli-
cations and ensure positive results. 
Conclusions
The Hamburg Classiication was a major advance in the un-
derstanding and management of CVMs. However, it is far 
from perfect and it will be modiied in the future according 
to the advances in knowledge of etiology, anatomy, embry-
ology, histology, pathology, physiology, hemodynamics and 
genetics. 
Diagnostic and therapeutic approach must be performed 
by a multidisciplinary group and not just by the surgeon. 
Ultrasound and MRI are the diagnostic tools of choice for the 
initial study of CVMs, subsequently complemented by a di-
agnostic approach according to each particular case. Surgi-
cal treatment of lesions is currently considered the gold 
standard. However, it is recommended to combine it with 
endovascular techniques like sclerotherapy or embolothera-
py. Extra-troncular CVMs are the most dificult to treat, with 
more recurrences and a poorer prognosis.
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